[an error occurred while processing this directive]
临床研究

肾脏替代治疗启动时机对重症急性肾损伤患者预后影响的Meta分析

  • 成慧昕 ,
  • 杜欣欣 ,
  • 李祥 ,
  • 杨春波 ,
  • 王毅 ,
  • 于湘友
展开
  • 830054 乌鲁木齐,1新疆医科大学第一附属医院重症医学科

收稿日期: 2022-06-13

  修回日期: 2022-08-17

  网络出版日期: 2022-11-12

基金资助

自治区区域协同创新专项(科技援疆计划)(2021E02064); 国家自然科学基金(82160360)

Timing of renal replacement therapy initiation for critically ill patients with acute kidney injury--a meta-analysis 

  • CHENG Hui-Xin ,
  • DU Xin-Xin ,
  • LI Xiang ,
  • YANG Chun-Bo ,
  • WANG Yi ,
  • YU Xiang-You
Expand
  • Department of Critical Care Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi  830054, China 

Received date: 2022-06-13

  Revised date: 2022-08-17

  Online published: 2022-11-12

摘要

目的  本研究旨在评价肾脏替代治疗(renal replacement therapy, RRT)的启动时机对重症急性肾损伤患者预后的影响。方法  检索PubMed、Web of Science、Embase、中国知网、万方数据知识服务平台、维普等数据库中有关肾脏替代治疗的不同启动时机对重症急性肾损伤患者影响的相关文献,检索时间限定为建库至2021年12月30日,文章类型限定为随机对照研究(randomized controlled study,RCT)。文献筛选、数据提取由2名研究者独立完成,主要结局指标为28天死亡率,次要结局指标为90天肾脏替代治疗需求以及相关并发症发生情况等,采用RevMan 5.3软件进行Meta分析,使用Cochrane偏倚风险工具评估偏倚风险。 结果 共纳入RCT 15篇,5709例重症患者,其中早期启动组2851例,晚期启动组2858例。Meta分析结果显示:早期启动组与晚期启动组死亡率差异无统计学意义(OR=0.96,95%CI:0.86~1.08,P=0.49)。晚期启动可以降低90天内患者对RRT的依赖(OR=1.57,95%CI:1.13~2.19,P<0.05),同时也可降低患者导管相关性血流感染(catheter related blood stream infection,CRBSI)、RRT相关性低血压及低磷血症的发生风险(CRBSI:OR =1.44,95%CI:1.06~1.95,P=0.02;低血压:OR=1.43,95%CI:1.17~1.76 P<0.05;低磷血症:OR=1.85 95%CI=1.02~3.35,P =0.04)。 结论 早期启动RRT不能降低重症急性肾损伤患者的死亡率,晚期启动RRT可以降低患者90天内对RRT的依赖并减少相关并发症的发生风险。

本文引用格式

成慧昕 , 杜欣欣 , 李祥 , 杨春波 , 王毅 , 于湘友 . 肾脏替代治疗启动时机对重症急性肾损伤患者预后影响的Meta分析[J]. 中国血液净化, 2022 , 21(11) : 795 -795-800,807 . DOI: 10.3969/j.issn.1671-4091.2022.11.003

Abstract

ackground  This study aimed to evaluate the impact of timing of renal replacement therapy (RRT) on prognosis in patients with severe acute kidney injury.  Methods  PubMed, Web of Science, Em-base, CNKI, Wanfang Data Knowledge Service platform, VIP and other databases were searched for literatures related to the influence of different start-up times of renal replacement therapy on patients with severe and complicated acute kidney injury. The retrieval time was limited to create database to December 30, 2021. The article type was limited to randomized controlled study (RCT). Literature screening and data extraction were independently completed by two researchers. The main outcome indicators were 28-day mortality, and the secondary outcome indicators were the need for renal replacement therapy at 90 days and the incidence of related complications. Meta-analysis was performed using RevMan 5.3 software. The Cochrane Risk of Bias Tool was used to assess the risk of bias in all studies.  Results  A total of 5709 severe patients were included in 15 RCTS in this study, including 2851 patients in the early initiation group and 2858 patients in the late initiation group. Meta-analysis showed that there was no significant difference in mortality between the early and late initiation groups [odds ratio (OR) = 0.96, 95%confidence interval (95% CI: 0.86~1.08, P =0.49]. Late initiation reduced RRT dependence within 90 days (OR=1.57, 95% CI:1.13~2.19, P <0.05), and the risk of catheter related blood stream infection (CRBSI), RRT-associated hypotension, and hypophosphatemia. (CRBSI:OR=1.4495%, CI:1.06~1.95, P =0.02; Hypotension: OR=1.4395% CI:1.17~1.76, P <0.05; Hypophosphatemia: OR=1.85, 95% CI:1.02~3.35, P =0.04).  Conclusions  Early RRT initiation does not reduce mortality in patients with severe AKI, but late RRT initiation can reduce RRT dependence within 90 days and the risk of related complications. 

参考文献


参考文献
[1] Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management[J]. Intensive Care Medicine, 2021,47(8):835-850.
[2] Ronco C, Bellomo R, A J. Acute kidney injury[J]. Lancet, 2019,394(10212):1949-1964.
[3] Hoste E A J, Bagshaw S M, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study[J]. Intensive Care Med, 2015,41(8):1411-1423.
[4] Neri M, Villa G, Garzotto F, et al. Nomenclature for renal replacement therapy in acute kidney injury: basic principles[J]. Critical Care, 2016,20(1).
[5] Rio A B L, Leite T T, de Oliveira Neves F M, et al. AKI Complications in Critically Ill Patients: Association with Mortality Rates and RRT[J]. 2015,10(1):21-28.
[6] See E J, Bellomo R. How I prescribe continuous renal replacement therapy[J]. Critical Care, 2021,25(1).
[7] Shingarev R, Wille K, Tolwani A. Management of Complications in Renal Replacement Therapy[J]. Semin Dial, 2011,24(2):164-168.
[8] Stéphane Gaudry M D, David Hajage M D, Fréderique Schortgen M D, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit[J]. 2016,375(2):122-133.
[9] Zarbock A, Kellum J A, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury[J]. JAMA, 2016,315(20):2190.
[10] S. D. Barbar, R. Clere-Jehl, A. Bourredjem, et al. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis[J]. The New England Journal of Medicine, 2018,379(15):1431-1442.
[11] Lumlertgul N, Peerapornratana S, Trakarnvanich T, et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial)[J]. Critical Care, 2018,22(1).
[12] Sean M. Bagshaw M D, Ron Wald M D, C. M. M P H N, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury[J]. The New England Journal of Medicine, 2020,383(3):240-251.
[13] Srisawat N, Laoveeravat P, Limphunudom P, et al. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: A feasibility study[J]. Journal of Critical Care, 2018,43:36-41.
[14] Wald R, Adhikari N K J, Smith O M, et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury[J]. Kidney Int, 2015,88(4):897-904.
[15] Jamale T E, Hase N K, Kulkarni M, et al. Earlier-Start Versus Usual-Start Dialysis in Patients With Community-Acquired Acute Kidney Injury: A Randomized Controlled Trial[J]. American Journal of Kidney Diseases, 2013,62(6):1116-1121.
[16] Combes A, Bréchot N, Amour J, et al. Early High-Volume Hemofiltration versus Standard Care for Post–Cardiac Surgery Shock. The HEROICS Study[J]. American Journal of Respiratory and Critical Care Medicine, 2015,192(10):1179-1190.
[17] 殷静静, 郑瑞强, 林华, 等. 持续肾脏替代治疗时机对感染性休克合并急性肾损伤患者预后的影响[J]. 实用临床医药杂志, 2018,22(7):63-66.
[18] 杨婷婷, 周瑞祥, 姚慧, 等. 连续性肾脏替代治疗时机选择对脓毒症急性肾损伤患者预后的影响[J]. 现代仪器与医疗, 2019,25(5):11-15.
[19] 李旭, 阿丽娅, 刘加明, 等. 脓毒症合并急性肾损伤3期患者启动肾脏替代治疗时机的研究[J]. 中国血液净化, 2018,17(10):652-657.
[20] Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial[J]. Lancet, 2021,397(10281):1293-1300.
[21] 陈锦源, 姚慧文, 周瑞辉, 等. 肾替代治疗时机对脓毒症急性肾损伤患者疗效的影响[J]. 黑龙江医学, 2019,43(7):725-726.
[22] 白准, 刘旭丽, 曾维忠, 等. 持续肾脏替代治疗时机对感染性休克合并急性肾损伤患者预后的影响[J]. 医学信息, 2020,33(8):116-117.
[23] Jiang Y, Xi X, Jia H, et al. Risk factors, clinical features and outcome of new-onset acute kidney injury among critically ill patients: a database analysis based on prospective cohort study[J]. BMC Nephrology, 2021,22(1).
[24] Zaragoza J J, Villa G, Garzotto F, et al. Initiation of Renal Replacement Therapy in the Intensive Care Unit in Vicenza (IRRIV) Score[J]. Blood Purification, 2015,39(1-3):246-257.
[25] 龚晓莹, 王睿, 李国福. 肾脏替代治疗开始时机对脓毒症急性肾损伤患者预后影响的Meta分析[J]. 中华危重病急救医学, 2015(9):712-717.
[26] Li X, Liu C, Mao Z, et al. Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis[J]. Critical Care, 2021,25(1).
[27] Kamboj M, Kazory A. Expanding the Boundaries of Combined Renal Replacement Therapy for Non-Renal Indications[J]. Blood purification, 2019,47(1-3):69-72.
[28] Roberts J A, Joynt G M, Lee A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients Data from the multinational SMARRT Study[J]. Clin Infect Dis, 2021,72(8):1369.
[29] Reynvoet E, Vandijck D M, Blot S I, et al. Epidemiology of infection in critically ill patients with acute renal failure[J]. Critical Care Medicine, 2009,37(7):2203-2209.
[30] Bell T, O Grady N P. Prevention of Central Line–Associated Bloodstream Infections[J]. Infectious Disease Clinics of North America, 2017,31(3):551-559.
[31] Augustine J J, Sandy D, Seifert T H, et al. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF[J]. American Journal of Kidney Diseases, 2004,44(6):1000-1007.
[32] Silversides J A, Pinto R, Kuint R, et al. Fluid balance, intradialytic hypotension, and outcomes in critically ill patients undergoing renal replacement therapy: a cohort study[J]. Critical care (London, England), 2014,18(6):624.
[33] Kelleher S P, Robinette J B, Miller F, et al. Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure[J]. Kidney international, 1987,31(3):725-730.
[34] Pistolesi V, Zeppilli L, Fiaccadori E, et al. Hypophosphatemia in critically ill patients with acute kidney injury on renal replacement therapies[J]. Journal of Nephrology, 2019,32(6):895-908.
[35] Yang Y, Zhang P, Cui Y, et al. Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury[J]. Critical care (London, England), 2013,17(5):R205.
[36] Lim C, Tan H K, Kaushik M. Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events[J]. Clinical Kidney Journal, 2017:w120.

文章导航

/

[an error occurred while processing this directive]